Venous thromboembolism, either deep vein thrombosis or pulmonary embolism, is a serious side-effect of postmenopausal hormone therapy.
Introduction
Despite recent data showing that overall health risks may exceed benefits from hormone therapy 1 , many women remain eligible for this treatment.
Women are mainly prescribed hormone therapy to treat postmenopausal climacteric symptoms. In addition, hormone therapy prevents osteoporosis.
Harmful effects of hormone therapy include breast cancer and venous thromboembolism 2 . Furthermore, randomised controlled trials showed that hormone therapy might increase the risk of coronary heart disease and stroke 1 , 3 .
Most previous studies of venous thromboembolism in hormone therapy users were done in USA among women using conjugated equine estrogens alone or combined with medroxyprogesterone acetate 1 , 3 . These results cannot be extrapolated to other types of hormone therapy used in Europe and especially to transdermal estrogens alone or combined with micronized progesterone.
The purpose of this review is to report the data on the risk of venous thromboembolism among hormone therapy users, taking into account the route of estrogen administration as well as the clinical background.
Incidence of venous thromboembolism
Venous thromboembolism is an uncommon disease before the menopause.
Its incidence markedly rises with increasing age after the menopause and reaches 1 per 100 over 75 years 4 . Venous thromboembolism commonly arises as a deep vein thrombosis but can also occur as a pulmonary embolism. Venous thrombosis may cause significant disability and/or death and, therefore, it is an important contributor to the burden of cardiovascular disease among postmenopausal women. Risk factors for venous thromboembolism include genetic background (thrombogenic mutation, protein deficit) and constitutional factors (overweight, obesity) but hormone use is also an important determinant of venous thromboembolism in women. THromboEmblism Risk) study, a French case/control study of venous thromboembolism, has been the first to establish a differential impact of hormone therapy on thrombotic risk by route of estrogen administration. This study has shown that transdermal estrogens might be safe with respect to thrombotic risk while oral estrogens increased this risk 6 . Although based on few data, a meta-analysis of epidemiological studies has recently shown an odds ratio for thrombosis close to one in transdermal estrogen users as compared with non-users (OR=1.2, 95% CI: 0.9-1.7) 5 . These results from observational studies need to be confirmed, especially in randomized controlled trials.
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Biological data
The impact of estrogens by route of administration on haemostasis has been investigated in randomised controlled trials which results are consistent with clinical data. Biological evidence lends support to the elevated thrombotic risk among users of oral estrogens and to the difference between estrogens by route of administration.
Among oral estrogens users, there is clear evidence for an increase in plasma levels of markers for in-vivo thrombin activation (prothrombin fragment 1+2) and lowered antithrombin activity in postmenopausal women, whereas transdermal estrogens have little or no effect on coagulation and fibrinolysis 7 .
In addition, oral estrogens significantly decrease total protein S plasma level 8 .
Activated protein C (APC) resistance has emerged as a risk factor for venous thrombosis 9 . Although this phenotype is mostly related to a single mutation in the factor V gene (R506Q or Leiden mutation) 10 , APC resistance detected in the absence of any thrombogenic mutation is also an independent risk factor for venous thromboembolism 11 . An acquired resistance to activated protein C has been found in users of oral estrogens 12 , but randomised trials have recently showed that these results did not apply to users of transdermal estrogens 13 . Changes in prothrombin fragment 1+2 plasma level are positively and significantly correlated with changes in ETP-based APCsr in factor V Leiden non-carriers allocated to oral estrogens. These biological data show that oral estrogens induce an APC resistance and activate blood coagulation, but these deleterious effects on coagulation do not apply to transdermal estrogen. These results emphasize the potential importance of the route of estrogen administration in prescribing estrogens.
Progestogens: another important determinant of the thrombotic risk
The impact of the progestogens on the risk of venous thromboembolism has been hardly studied among women using hormone therapy. Final results of the ESTHER study have shown an increase in the risk of venous thromboembolism among users of norpregnane derivatives (nomegestrol acetate or promegestone). However, micronized progesterone or pregnane 5/9 derivatives were not associated with an increased thrombotic risk 14 . These results have just been confirmed by the data from the E3N study which also suggest a deleterious effect of nortestosterone derivatives on thrombotic risk 15 . These data come from observational studies which are subject to bias and the results must therefore be cautiously interpreted. They need to be confirmed, especially in randomised controlled trials.
Data regarding the progestogen effects on haemostasis are scarce. However, randomised controlled trials have shown no change in haemostasis in women using transdermal estrogens combined with micronized progesterone 7 , 13 .
These results lend a biological support to the potential safety of micronized progesterone. Investigations regarding the impact of norpregnane derivatives on coagulation are ongoing.
Hormone therapy in women at high risk for venous thromboembolism: advantages for transdermal estrogens
The risk of venous thromboembolism increases with age and elevated bodymass index. Factor V Leiden mutation and prothrombin G20210A mutation are also important thrombotic risk factors. Few data regarding the impact of hormone therapy among women at high thrombotic risk are available.
Thrombogenic mutations
Factor V Leiden mutation and prothrombin G20210A mutation are the two most common genetic defects associated with an increased thrombotic risk 5 .
Their prevalence is close to 5% and 2% respectively in a Caucasian population. Some studies have investigated the combination of a prothrombotic mutation and oral estrogen use on the risk of venous thromboembolism. Using the non-users without any mutation as the reference group, oral estrogens users who carry one prothrombotic mutation represent a group at high thrombotic risk 5 . In 2005, the ESTHER study gave the opportunity to investigate the impact of hormone therapy by route of estrogen administration and prothrombotic mutations on the risk of venous thrombosis.
6/9
These results have shown for the first time that transdermal estrogens did not confer an additional risk on women with a mutation 16 .
Overweight and obesity
The impact of elevated body-mass index on thrombotic risk has been studied alone and together with oral estrogens use. Already twofold increased in women with an elevated body-mass index, the risk of venous thromboembolism is further enhanced among oral estrogens users with an overweight 5 . However, results from the ESTHER study have recently shown that transdermal estrogens did not increase the thrombotic risk among women with an overweight or obesity 17 .
Hormone therapy and venous thromboembolism: individual genetic susceptibility
Some enzymes including cytochromes P450 are implicated in the sex hormone metabolism and can modulate the estrogens biodisponibility. 
Clinical implications, conclusions and perspectives
Hormone replacement therapy can improve the quality of life for women with hypo-oestrogenic symptoms 19 
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